Ticker LaunchReverse merger · Completed · KLRS
Kalaris Tx, Inc.
Reverse merger with AlloVir, Inc.
Kalaris Tx, Inc. merged into AlloVir, Inc., a Nasdaq-listed clinical-stage biotech that funded Kalaris with a convertible note before closing, in a reverse merger that takes the private company public. The deal was announced on Nov 7, 2024 and closed on Mar 18, 2025. The combined company trades as Kalaris Therapeutics, Inc. (KLRS) on Nasdaq.
Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing TH103, an anti-VEGF agent engineered for longer-lasting and increased activity in neovascular and exudative retinal diseases. TH103 is in a Phase 1 trial in neovascular age-related macular degeneration, with initial data expected in the second half of 2025.
- Status
- Completed
- Private company
- Kalaris Tx, Inc.
- Public company
- AlloVir, Inc.
- Public company business before
- Nasdaq-listed clinical-stage biotech that funded Kalaris with a convertible note before closing
- Announced
- Nov 7, 2024
- Closed
- Mar 18, 2025
- Combined company
- Kalaris Therapeutics, Inc. (KLRS)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Closing 8-K Mar 18, 2025
- Closing press release
- Announcement press release
- All filings on EDGAR CIK 1754068
Other completed reverse mergers
- SRx Health Solutions, Inc.into Better Choice Company, Inc. · Apr 24, 2025
- METech Recycling, Inc.into First America Resources Corp · Apr 21, 2025
- Tvardi Therapeutics, Inc.into Cara Therapeutics, Inc. · Apr 15, 2025
- Synthesis Analytics Production Ltdinto Edgemode, Inc. · Apr 7, 2025
- Premier Air Charter, Inc.into Altair International Corp. · Mar 5, 2025
- Adaptin Bio, Inc.into Unite Acquisition 1 Corp. · Feb 11, 2025